[{"address1": "2001 Market Street", "address2": "Suite 3915 Unit #15", "city": "Philadelphia", "state": "PA", "zip": "19103", "country": "United States", "phone": "(267) 225-7416", "website": "https://www.contexttherapeutics.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Context Therapeutics Inc., a biopharmaceutical company, develops products for the treatment of solid tumors. Its lead program candidate is CTIM-76, an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. The company has a collaboration and licensing agreement with Integral Molecular, Inc. for the development of a CLDN6 bispecific monoclonal antibody for cancer therapy. Context Therapeutics Inc. was incorporated in 2015 and is headquartered in Philadelphia, Pennsylvania.", "fullTimeEmployees": 5, "maxAge": 86400, "priceHint": 4, "previousClose": 2.17, "open": 2.17, "dayLow": 1.9501, "dayHigh": 2.23, "regularMarketPreviousClose": 2.17, "regularMarketOpen": 2.17, "regularMarketDayLow": 1.9501, "regularMarketDayHigh": 2.23, "beta": 2.322, "forwardPE": -6.7500005, "volume": 4119550, "regularMarketVolume": 4119550, "averageVolume": 698546, "averageVolume10days": 754890, "averageDailyVolume10Day": 754890, "bid": 2.1, "ask": 2.21, "bidSize": 500, "askSize": 200, "marketCap": 161996336, "fiftyTwoWeekLow": 0.77, "fiftyTwoWeekHigh": 2.24, "fiftyDayAverage": 1.75488, "twoHundredDayAverage": 1.26715, "currency": "USD", "enterpriseValue": 151907152, "floatShares": 43872513, "sharesOutstanding": 74998304, "sharesShort": 1005405, "sharesShortPriorMonth": 40409, "sharesShortPreviousMonthDate": 1713139200, "dateShortInterest": 1715731200, "sharesPercentSharesOut": 0.0134000005, "heldPercentInsiders": 0.02781, "heldPercentInstitutions": 0.46948, "shortRatio": 0.75, "shortPercentOfFloat": 0.0136, "impliedSharesOutstanding": 74998304, "bookValue": 0.529, "priceToBook": 4.083176, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1711843200, "netIncomeToCommon": -21323690, "trailingEps": -1.33, "forwardEps": -0.32, "enterpriseToEbitda": -6.837, "52WeekChange": 0.6363636, "SandP52WeekChange": 0.26238096, "exchange": "NCM", "quoteType": "EQUITY", "symbol": "CNTX", "underlyingSymbol": "CNTX", "shortName": "Context Therapeutics Inc.", "longName": "Context Therapeutics Inc.", "firstTradeDateEpochUtc": 1634736600, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EDT", "uuid": "9370db4d-3fc8-33de-8dd0-aba14eeca611", "messageBoardId": "finmb_408000800", "gmtOffSetMilliseconds": -14400000, "currentPrice": 2.16, "targetHighPrice": 10.0, "targetLowPrice": 2.1, "targetMeanPrice": 5.4, "targetMedianPrice": 4.75, "recommendationMean": 2.0, "recommendationKey": "buy", "numberOfAnalystOpinions": 4, "totalCash": 10089207, "totalCashPerShare": 0.135, "ebitda": -22218150, "quickRatio": 3.868, "currentRatio": 4.232, "returnOnAssets": -0.64594, "returnOnEquity": -1.1471701, "freeCashflow": -12273985, "operatingCashflow": -19679784, "financialCurrency": "USD", "trailingPegRatio": null, "__fetch_time": "2024-06-24"}]